Abiraterone acetate in men with metastatic castration-resistant prostate cancer and no prior chemotherapy: A double-arm, multiple-centre, phase III clinical study
单位：[1]Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong Universityof Science and Technology, Wuhan, China华中科技大学同济医学院附属同济医院泌尿外科[2]Department of Urology, West ChinaHospital, Sichuan University, Chengdu, China[3]Department of Urology, Renji HospitalAffiliated Shanghai Jiao Tong University School of Medicine, Shanghai, China[4]Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China[5]Department of Urology, Qilu Hospital of Shandong University, Jinan, China[6]Department of Urology, Chongqing Cancer Hospital, Chongqing, China[7]Departmentof Urology, The Second Affiliated Hospital, School of Medicine, Zhejiang University,Hangzhou, China[8]Department of Urology, The First Affiliated Hospital of Jilin University, Changchun, China[9]Department of Urology, Peking University First Hospital,Beijing, China[10]Department of Urology, The First Affiliated Hospital of NanjingMedical University, Nanjing, China[11]Department of Urology, Wuhan General Hospitalof Guangzhou Military Region, Wuhan, China[12]Department of Urology, Henan CancerHospital, Zhengzhou, China[13]Department of Urology, Collaborative Innovation Centerfor Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China[14]Department of Urology, Gansu Cancer Hospital, Lanzhou, China[15]Department ofUrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China[16]Department of Medicine, Affiliated Tumor Hospital of Harbin Medical University,Harbin, China[17]Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
第一作者单位：[1]Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong Universityof Science and Technology, Wuhan, China
推荐引用方式(GB/T 7714)：
Z. Hu,Z. Ye,H. Zeng,et al.Abiraterone acetate in men with metastatic castration-resistant prostate cancer and no prior chemotherapy: A double-arm, multiple-centre, phase III clinical study[J].ANNALS OF ONCOLOGY.2020,31:S530-S530.doi:10.1016/j.annonc.2020.08.908.
APA：
Z. Hu,Z. Ye,H. Zeng,Y. Huang,D. Ye...&H. Li.(2020).Abiraterone acetate in men with metastatic castration-resistant prostate cancer and no prior chemotherapy: A double-arm, multiple-centre, phase III clinical study.ANNALS OF ONCOLOGY,31,
MLA：
Z. Hu,et al."Abiraterone acetate in men with metastatic castration-resistant prostate cancer and no prior chemotherapy: A double-arm, multiple-centre, phase III clinical study".ANNALS OF ONCOLOGY 31.(2020):S530-S530
医学